Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 01, 2024 08:00 ET
|
Immuneering Corporation
- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104...
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
February 26, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 20, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 20, 2024 08:00 ET
|
Immuneering Corporation
– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma – – Company expects multiple readouts from its Phase...
Revolution Medicines to Participate in Upcoming Investor Conferences
February 01, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
January 04, 2024 08:00 ET
|
Quanta Therapeutics, Inc.
QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Blue Star Foods Provides Shareholder Update
November 27, 2023 09:00 ET
|
Blue Star Foods Corp.
Evaluating Several Strategic Acquisitive and Organic Growth Opportunities Miami, FL, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”)...
Revolution Medicines Completes Acquisition of EQRx
November 09, 2023 09:10 ET
|
Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
November 08, 2023 11:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for...